Geneva, Switzerland and Boston, MA – 30 August, 2017 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics…
Category: Press release
The press releases from ObsEva
ObsEva Reports Second Quarter 2017 Financial Results and Provides Business Update
– Patient Enrollment Progressing for late stage clinical programs in Assisted Reproductive Technology, Uterine Fibroids, and Endometriosis – Geneva, Switzerland and Boston,…
ObsEva SA to Hold Second Quarter 2017 Financial Results/Business Update Call on August 15, 2017 and Present at Wedbush PacGrow Healthcare Conference in NYC on August 16, 2017
Geneva, Switzerland and Boston, MA – 07 August, 2017 – ObsEva SA (NASDAQ: OBSV), a Swiss biopharmaceutical company focused on the development and commercialization of novel therapeutics…
ObsEva Announces Presentations Related to its Assisted Reproductive Technology (ART) and Pre-term labor (PTL) Development Programs at ESHRE 2017 Annual Meeting
Phase 2 nolasiban previously reported data supports potential for meaningfully increasing live birth rates in ART Non-clinical results of OBE022…
ObsEva SA Announces the Completion of a Phase 1 PK/PD Clinical Trial Evaluating Different Doses of OBE2109 and Add-Back Therapy
– OBE2109 is a GnRH receptor antagonist currently in development as both a stand-alone treatment and with add-back therapy designed…
ObsEva SA to Attend Jefferies Healthcare Conference in NYC
Geneva, Switzerland and Boston, MA – 31 May 2017 – ObsEva SA (Nasdaq: OBSV), a Swiss biopharmaceutical company focused on the development and commercialization of novel therapeutics…
ObsEva Reports First Quarter 2017 Financial Results and Business Update
– Phase 3 Programs Underway in Uterine Fibroids and Assisted Reproduction Technology (ART) – Geneva, Switzerland and Boston, MA – May 18, 2017 – ObsEva SA (NASDAQ:…
ObsEva Announces the Completion of a Phase 1 Drug-Drug Interaction Study with OBE022
– OBE022 is ObsEva’s potential first-in-class, oral and selective PGF2alpha receptor antagonist for the treatment of preterm labor – Geneva, Switzerland and Boston, MA – 18…
ObsEva SA to Attend BioEquity Europe 2017 in Paris
Geneva, Switzerland – 16 May 2017 – ObsEva SA (Nasdaq: OBSV), a Swiss biopharmaceutical company focused on the development and commercialization of novel therapeutics for…
ObsEva SA to Hold First Quarter 2017 Financial Results and Business Update Call on Thursday, May 18, 2017
Geneva, Switzerland and Boston, MA – May 11, 2017 – ObsEva SA (Nasdaq: OBSV), a Swiss biopharmaceutical company focused on the development and commercialization of novel therapeutics…